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Foreword
Chronic hyperglycemia and development of diabetes-
speciﬁc microvascular complications in the retina, renal
glomerulus, and peripheral nerve are characteristic of all forms
of diabetes. As a consequence of its microvascular pathology,
diabetes is the leading cause of blindness, end-stage renal dis-
ease, and a variety of debilitating neuropathies. Diabetics are
the fastest growing group of renal dialysis and transplant recip-
ients, and in the United States, their 5-year survival rate is only
21%, worse overall than that for all forms of cancer combined.
Over 60% of diabetic patients suffer from neuropathy, which
includes mononeuropathies, distal symmetrical polyneuropa-
thy, and a variety of autonomic neuropathies causing erectile
dysfunction,urinaryincontinence,gastroparesis,andnocturnal
diarrhea. Fifty percent of all non-traumatic amputations in the
United States are due to diabetic peripheral neuropathy, often
in conjunction with lower extremity arterial disease.
The causal link between diabetes and microvascular com-
plications is chronic hyperglycemia. Large prospective clinical
studies in both Type I and Type II diabetics have demonstrated
a strong relationship between glycemia and diabetic microvas-
cular complications.
Diabetes-speciﬁc microvascular disease in the retina,
glomerulus, and peripheral nerve is characterized by shared
pathophysiologic features. A large body of evidence from clin-
ical trials and animal studies has demonstrated that chronic
hyperglycemia is the critical initiating factor for all types of
microvascular disease. Both duration and magnitude of hyper-
glycemia are strongly correlated with the extent and rate of
progressionofdiabeticmicrovascularcomplications.Although
all diabetic cells are exposed to elevated levels of plasma glu-
cose, hyperglycemic damage is limited to those cell types (e.g.
endothelialcells)thatareunabletodownregulateglucosetrans-
port into the cell, leading to intracellular hyperglycemia. Fur-
ther evidence that intracellular hyperglycemia is the critical
factor in the development of diabetic pathology is the fact that
GLUT-1 overexpression in mesangial cells cultured under nor-
moglycemic conditions induces the same increase of collagen
type I and IV, and ﬁbronectin gene expression as does hyper-
glycemia in mesangial cells that don’t overexpress GLUT-1.
Early in the course of diabetes, in the absence of struc-
tural changes, intracellular hyperglycemia causes abnormali-
ties in blood ﬂow and increased vascular permeability. The
resulting increase in blood ﬂow and intracapillary pressure
reﬂects decreased activity of vasodilators such as nitric ox-
ide, increased activity of vasoconstrictors such as angiotensin
II and endothelin-1, and elaboration of permeability factors
such as VEGF. As a consequence, retinal capillaries exhibit in-
creased leakage of ﬂourescein and glomerular capillaries show
an increased albumin excretion rate. Initially this process is re-
versible, however quantitative and qualitative abnormalities of
the extracellular matrix contribute to an irreversible increase
in vascular permeability. With time, microvascular cell loss, in
partduetoprogrammedcelldeath,andprogressivecapillaryoc-
clusion occur, due both to extracellular matrix overproduction
induced by growth factors such as TGFβ, and to deposition of
extravasatedperiodicacid-Schiff-positiveplasmaproteins.Hy-
perglycemia may also decrease production of trophic factors
for endothelial and neuronal cells. Connective tissue growth
factor (CTGF), a key intermediate molecule involved in the
pathogenesis of ﬁbrosing chronic diseases, has recently been
shown to be overexpressed in kidney, myocardium and aorta
from diabetic animals as well, implicating CTGF in the patho-
genesis of both micro- and macrovascular diabetic complica-
tions. Together, the pathophysiologic events described above
lead to edema, ischemia, and hypoxia-induced neovasculariza-
tion in the retina, to proteinuria, mesangial matrix expansion
and glomerulosclerosis in the kidney, and to multifocal axonal
degeneration in peripheral nerves.
In this timely and important special issue, the authors add
valuable new information, about an emerging paradigm in the
pathogenesis of diabetic complications: the role of decreased
levelsofcriticaltrophicfactorssuchasinsulinlikegrowthfactor
I(IGF-1),nervegrowthfactor(NGF)andrelatedneuropeptides,
and proinsulin-derived C-peptide. This paradigm has obvious
immediate therapeutic implications, because replacing abnor-
mally low levels of trophic factors may well have a beneﬁcial
effectinthepreventionandtreatmentofdiabeticcomplications.
Like all good science, this special issue of Experimental
Diabesity Research raises new important questions as well.
First, it is now well-established that each of the four major
biochemical pathways underlying diabetic complications re-
ﬂect a single hyperglycemia-induced process: overproduction
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of superoxide by the mitochondrial electron transport chain.
How does this process lead to changes in expression of trophic
factors, damaging cytokines and growth factors, and their
receptors? Even more fascinating is the difference in IGF-1
expression in Type I vs Type II diabetic patients. These
data raise the question, now being asked under the rubric of
“Systems Biology,” about the importance of the temporal, and
well as the quantitative dimension. For both hyperlglycemic
exposure, as well as cytokine and growth factor exposure, the
temporal pattern, both short- and long-term, are likely to play a
very important role in determining the net effect of both. After
reading this publication, I am more convinced than ever that
the answers to these important questions will emerge over the
next few years.
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